Everything below concerns GHRH analogue. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-01-04. Where a claim depends on a specific study, the study is described rather than over-claimed.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Pharmacodynamic studies show that tesamorelin reduces visceral adipose tissue more than subcutaneous adipose tissue in the studied population. This selectivity may relate to differences in blood flow and hormone sensitivity between fat depots. Effects on glucose metabolism and insulin sensitivity have been investigated, with some trials reporting modest changes and others showing stability. The precise relationship between growth hormone exposure, IGF-1 levels, and visceral fat loss remains an active area of analysis.
Tesamorelin binds to growth hormone-releasing hormone receptors on somatotroph cells in the anterior pituitary. Receptor activation increases intracellular cyclic AMP and promotes synthesis and secretion of growth hormone. Because the peptide mimics endogenous GHRH, it amplifies the normal pulsatile release of growth hormone rather than providing exogenous growth hormone directly. This upstream action distinguishes tesamorelin from recombinant growth hormone preparations and from growth hormone secretagogues that act at different receptors.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic 44-residue GHRH analog | Sequence matches human GHRH(1-44); differs only at the N-terminus |
| Nominal molecular mass | Approximately 5,136 Da (free base) | Small variation arises from counterion and salt form |
| Appearance | White to off-white lyophilized powder | Supplied in single-use vials intended for reconstitution |
| Solubility class | Freely soluble in water | Practically insoluble in nonpolar organic solvents |
| Typical storage | 2 to 8 degrees Celsius, protected from light | Reconstituted material is handled according to label instructions |
The peptide is synthesized chemically rather than extracted from biological sources. Solid-phase synthesis builds the chain from the C-terminus toward the N-terminus, after which the hexenoyl group is attached. Purity is typically assessed by high-performance liquid chromatography, and identity is confirmed by mass spectrometry. Regulatory review of the finished product focuses on these analytical controls, since small deviations in sequence or modification can change biological activity. Questions about long-term effects on the pituitary axis remain areas of continued investigation.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone (GHRH) family. Its sequence corresponds to the fully active 44-amino-acid form of human GHRH, with a single structural modification: the addition of a trans-3-hexenoyl group at the N-terminus. That modification is not found in the naturally occurring hormone and was introduced deliberately during development to improve stability against enzymatic degradation. The compound is therefore best described as a stabilized analogue rather than a naturally occurring peptide.
The native hormone is produced in the hypothalamus and acts on the anterior pituitary. Binding of GHRH to its receptor stimulates synthesis and release of growth hormone into circulation. Because the analogue retains the receptor-binding region of the parent sequence, it engages the same receptor and triggers the same downstream signaling. The result is increased growth hormone secretion from pituitary cells, which in turn influences hepatic production of insulin-like growth factor 1. This axis is the basis for the compound's measured biological effects.
Tesamorelin binds the growth hormone–releasing hormone receptor on pituitary somatotroph cells. The receptor signals through the Gs protein, raising intracellular cAMP and activating protein kinase A. That cascade triggers release of stored growth hormone in pulses rather than a steady stream. Because the drug acts at the receptor that normally controls this process, its effect depends on the body's own signaling architecture rather than on a synthetic pathway. The resulting hormone profile reflects the timing of each pulse, not only its size.
Measured responses usually involve growth hormone and insulin-like growth factor 1, known as IGF-1. Growth hormone rises in bursts and is difficult to sample reliably, while IGF-1 shifts more slowly and can be assessed from a single blood draw. Studies therefore treat IGF-1 as the more practical pharmacodynamic marker. Both are indirect, showing that the receptor was engaged rather than that the peptide reached a particular concentration. Direct exposure measurement requires an assay aimed at the molecule itself.
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
Tesamorelin acts on the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in intracellular cyclic AMP, which in turn opens ion channels and raises calcium concentrations, leading to release of stored growth hormone into the bloodstream. Because the peptide works through the same receptor as the body's own GHRH, the resulting secretion follows a pulsatile pattern rather than a continuous elevation. The N-terminal modification slows enzymatic breakdown, so the signal persists longer than it would with the unmodified hormone.
Growth hormone released from the pituitary stimulates the liver and other tissues to produce insulin-like growth factor 1, a stable circulating protein that serves as a practical marker of activity. Clinical studies therefore track IGF-1 concentrations alongside the hormone itself, and they commonly measure body composition with imaging rather than relying on body weight alone. Visceral adipose tissue, the fat surrounding abdominal organs, is quantified by computed tomography in the studies that supported approval. Adverse effects reported in trials include injection-site reactions, joint pain, and increases in blood glucose, which is why monitoring accompanies use.
Questions remain about how much of the observed fat reduction reflects direct GHRH-receptor signaling versus the downstream growth hormone and IGF-1 surge. It is also unclear whether the compound produces meaningful benefit in populations without lipodystrophy, since trials in cognitive impairment did not reach their stated goals. Long-term effects on glucose metabolism and on cardiovascular outcomes are not fully characterized. Published work generally describes effects on surrogate markers rather than on hard clinical endpoints, and independent replication of some findings is limited.
===== MeSH D08.811.682.608 – nadh, nadph oxidoreductases ===== MeSH D08.811.682.608.047 – apoptosis inducing factor MeSH D08.811.682.608.191 – cytochrome reductases MeSH D08.811.682.608.191.237 – cytochrome-b(5) reductase MeSH D08.811.682.608.191.500 – nadph-ferrihemoprotein reductase MeSH D08.811.682.608.504 – electron transport complex i MeSH D08.811.682.608.504.500 – nadh dehydrogenase MeSH D08.811.682.608.530 – nadh tetrazolium reductase MeSH D08.811.682.608.540 – nadp transhydrogenase MeSH D08.811.682.608.550 – nadph dehydrogenase MeSH D08.811.682.608.575 – nadph oxidase MeSH D08.811.682.608.800 – quinone reductases MeSH D08.811.682.608.800.500 – nad(p)h dehydrogenase (quinone) MeSH D08.811.682.608.800.500.500 – zeta-crystallins
Following the initial sequential resonance assignment, it is usually possible to extend the assignment from the Cα and Cβ to the rest of the sidechain using experiments such as HCCH-TOCSY, which is basically a TOCSY experiment resolved in an additional carbon dimension.
=== Gaming Control Board === While secretary of revenue, Kennedy was also appointed to the Louisiana Gaming Control Board, which is responsible for regulating legalized gambling. He criticized riverboat casino operators for failing to enforce the 21-year age restriction.
A lobotomy (from Greek λοβός (lobos) 'lobe' and τομή (tomē) 'cut, slice') or leucotomy is a discredited form of neurosurgical treatment for psychiatric disorder or neurological disorder (e.g. epilepsy, depression) that involves severing connections in the brain's prefrontal cortex. The surgery severs most of the connections to and from the prefrontal cortex, and the anterior part of the frontal lobes of the brain. From the 1930s until the 1970s, the treatment was used for handling psychiatric disorders as a mainstream procedure in some countries. A preoccupation with the ability to work and personal responsibility over patient well-being were contributing factors to the prevalence of lobotomies in the United States. The originator of the procedure, Portuguese neurologist António Egas Moniz, shared the Nobel Prize for Physiology or Medicine of 1949 for the "discovery of the therapeutic value of leucotomy in certain psychoses", although the awarding of the prize has been subject to controversy. The procedure was modified and championed by Walter Freeman, who performed the first lobotomy at a mental hospital in the United States in 1936. Its use increased dramatically from the early 1940s and into the 1950s; by 1951, almost 20,000 lobotomies had been performed in the US and proportionally more in the United Kingdom. More lobotomies were performed on women than on men: a 1951 study found that nearly 60% of American lobotomy patients were women, and limited data shows that 74% of lobotomies in Ontario from 1948 to 1952 were performed on female patients.
==== Symptoms ==== Necrosis may be symptomatic or asymptomatic. Symptomatic necrosis involves lingering pain response to hot and cold stimuli, spontaneous pain that may cause a patient to awaken during sleep, difficulty eating and sensitivity to percussion. Asymptomatic necrosis is non-responsive to thermal stimuli or electric pulp tests, leaving the patient unaware of the pathology.
Sources: en.wikipedia.org
Ian Gribbin, the Reform UK candidate for Bexhill and Battle, apologises after saying the UK would be "far better" if it had "taken Hitler up on his offer of neutrality" instead of fighting World War II. Reform UK leader Nigel Farage gives his personal backing to two Democratic Unionist Party candidates despite his party's alliance with Traditional Unionist Voice. 11 June – A 28-year-old man is arrested on suspicion of public order offences after objects are thrown at Nigel Farage during a campaign tour in Barnsley. Rishi Sunak unveils the Conservative Party's general election manifesto, which includes a further cut in National Insurance, a halving of immigration, and several new housing policies. BBC Scotland airs an election debate featuring the leaders of Scotland's five main political parties: John Swinney (SNP), Douglas Ross (Scottish Conservatives), Anas Sarwar (Scottish Labour), Alex Cole-Hamilton (Scottish Liberal Democrats) and Lorna Slater (Scottish Greens). Sophie Raworth pulls out of presenting the BBC's The Prime Ministerial Debate, scheduled to air on 26 June, after fracturing her ankle; Mishal Husain will present instead. Robin Harper, a former leader of the Scottish Greens, joins Scottish Labour, citing his former party's failure on the environment for his decision. Vaughan Gething tells the Senedd he regrets the "impact" of his decision to accept a £200,000 donation from a man whose company was convicted of illegally dumping waste.
According to Kate Brown, the plutonium production plants at Hanford and Mayak in Russia, over a period of four decades, "both released more than 200 million curies of radioactive isotopes into the surrounding environment—twice the amount expelled in the Chernobyl disaster in each instance". Most of this radioactive contamination over the years were part of normal operations, but unforeseen accidents did occur and plant management kept this secret, as the pollution continued unabated. In 2004, a safe was discovered during excavations of a burial trench at the Hanford nuclear site. Inside the safe were various items, including a large glass bottle containing a whitish slurry which was subsequently identified as the oldest sample of weapons-grade plutonium known to exist. Isotope analysis by Pacific Northwest National Laboratory indicated that the plutonium in the bottle was manufactured in the X-10 Graphite Reactor at Oak Ridge during 1944.
Much of the research on cell reproduction came together in August Weismann's theory of heredity: he identified the nucleus (in particular chromosomes) as the hereditary material, proposed the distinction between somatic cells and germ cells (arguing that chromosome number must be halved for germ cells, a precursor to the concept of meiosis), and adopted Hugo de Vries's theory of pangenes. Weismannism was extremely influential, especially in the new field of experimental embryology. By the mid-1850s the miasma theory of disease was largely superseded by the germ theory of disease, creating extensive interest in microorganisms and their interactions with other forms of life. By the 1880s, bacteriology was becoming a coherent discipline, especially through the work of Robert Koch, who introduced methods for growing pure cultures on agar gels containing specific nutrients in Petri dishes. The long-held idea that living organisms could easily originate from nonliving matter (spontaneous generation) was attacked in a series of experiments carried out by Louis Pasteur, while debates over vitalism vs. mechanism (a perennial issue since the time of Aristotle and the Greek atomists) continued apace.
PfSSM (2008), CBM and CCF (2008) for Plasmodium proteins, which have a different amino acid evolutionary bias due to the low GC content of the genome. Matrices for transmembrane proteins. JTT transmembrane (1994) is the first of the class. Later work include: For alpha-helical transmembrane proteins, PHAT (2000) and SLIM (2001). For beta-barrel transmembrane proteins, bbTM (2008). Matrices for a specific protein family, including GPCRtm (2015) for the transmembrane (mostly helical) regions of GPCRs. Matrices for proteins with a specific role, including Hubsm (2017) for "hub proteins" in protein‐protein interaction networks. Matrices for intrinsically disordered proteins, including DUNMat (2002), MidicMat (2009), Disorder (2010), and EDSSMat (2019).
Sources: en.wikipedia.org
It is a synthetic peptide built from 44 amino acids arranged in the same order as human growth hormone-releasing hormone. A short fatty-acid chain, described as a trans-3-hexenoyl group, is attached to the first amino acid. The finished molecule is formulated as a sterile powder that is dissolved before use.
No. It is a releasing-factor analog that signals the pituitary gland to secrete growth hormone, whereas recombinant growth hormone is the hormone itself administered directly. The two are chemically distinct and act at different points in the same endocrine pathway. This distinction is often lost in informal discussion.
Native growth hormone-releasing hormone is broken down within minutes by dipeptidyl peptidase-4 in the bloodstream. Adding the hexenoyl group at the N-terminus shields the peptide from that enzyme. The modification does not change the receptor it targets, only how long the peptide survives in circulation.
It targets the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Binding stimulates cyclic AMP signaling and growth hormone secretion. This is the same receptor used by endogenous GHRH.